P. Mahoney

Oral oseltamivir reduces febrile illness in patients considered at high risk of influenza complications

P. Ward, C. Martín, P. Mahoney, 2001 .

Effective treatment of influenza with oral oseltamivir in a vaccinated population of high-risk patients

P. Ward, M. Zaug, P. Mahoney, 2001 .

Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study

R. Recker, R. Weinstein, P. Meunier, 2004, Osteoporosis International.

The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast.

C. Christiansen, L. Tankó, M. McClung, 2003, Bone.

Growth and development following marrow transplantation for leukemia.

H. Deeg, K. Sullivan, F. Appelbaum, 1986, Blood.

Growth and development following marrow transplantation for leukemia.

H. Deeg, K. Sullivan, F. Appelbaum, 1986, Blood.

Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

P. Ward, F. Hayden, L. Kaiser, 2003, Archives of internal medicine.

Vertebral fracture diagnosis in the multinational BONE study of oral ibandronate: quality management in radiology.

D. Felsenberg, G. Armbrecht, G. von Ingersleben, 2008, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Efficacy and safety of ibandronate given by intravenous injection once every 3 months.

C. Christiansen, D. Felsenberg, P. Delmas, 2004, Bone.

Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women

J. Stakkestad, J. Stepan, A. Nordby, 2003, Annals of the rheumatic diseases.

Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.

C. Christiansen, P. Delmas, R. Recker, 2004, Bone.